On 18 February, a launch ceremony was held in Macau for Macau Biotech Company jointly established by Namyue Group and Shenzhen Yhlo Biotech Co., Ltd.

The two companies intend to take the biotech company as the main body, give full play to their respective advantages and jointly invest CNY 6.2 billion yuan to build a biotechnology industrial park in the Hengqin Guangdong-Macau In-depth Cooperation Zone, focusing on providing the whole chain of services such as research and development, production, manufacturing and sales of sequencing instruments, reagents and chips, attracting high-quality upstream and downstream enterprises of the industry chain, creating a source of original technology, building a Qin-Macau health industry ecosystem, and helping moderate and diversified development of Macao economy.

Mr Zhou Xingting, Chairman of Namyue Group, Mr Hu Deming, Founder of YHLO, Mr Xiao Yujin, Deputy General Manager of YHLO and Chairman of Zhuhai Dadao Sequencing Biotechnology Co., Ltd. attended the launch ceremony. 

Mr Zhou Xingting said that as a Guangdong company in Macao, Namyue Group has been following the direction of the bay area, focusing on the needs of Macao and giving full play to promote the high-quality development of the pharmaceutical and health industry. The in-depth cooperation with YHLO is Namyue Group’s important initiative to implement the strategic deployment of the provincial government and promote high-quality development. Both sides will make good use of their resource advantages, accelerate the industrial park construction and strive to start and complete construction in the same year. We will join hands to build a science and innovation platform, gathering innovation resources, promoting the domestic substitution of high-end medical devices, cracking the "neck" problems, striving towards the goal of “Manufacturing takes charge”, gradually cultivating 10 listed firms in the future and helping the construction of the pharmaceutical highland and international science and technology innovation center in the Guangdong-Hong Kong-Macao Greater Bay Area.

Mr Hu Deming said that YHLO is committed to the research and development, production, sales and services of in vitro diagnostic products in the biomedical industry and is a listed company with a large amount of independent intellectual property rights. This cooperation with Namyue Group intends to take cutting-edge products including gene sequencing and precision medicine, which have already been registered and mass-produced by Dadao Sequencing, as the entry point. Based on the cooperation principle of "complementary advantages, resource sharing and mutual benefit", we will dig deeper into the cooperation potential, accelerate the landing and construction of the great health industrial park and contribute to the development of Qin-Macao integration.